ClinicalTrials.gg
CompletedNCT03286218Updated Jan 10, 2020Results posted

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

A Phase 1 interventional study of Lasmiditan and Alprazolam in Recreational Drug Use and Prescription Drug Abuse (Not Dependent), sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.

Enrollment
772nd of 1,447
96 · median 104
Started
2017
with 73 others
Phase 1
131 of 1,589
14 open now
Registered
886th of 1,589
by date

Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 772nd largest by enrollment of the 1,447 interventional ones that give a count, is one of 74 that started in 2017, is one of 131 in phase 1, and was the 886th registered.

Substance-Related Disorders

2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,589 studies in Substance-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the abuse potential of study drug lasmiditan.

Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth).

This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.

03

Conditions studied

  • Recreational Drug Use
  • Prescription Drug Abuse (Not Dependent)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination.
  • Have a (BMI) of 18 to 32 kilograms per meter squared (kg/m²) inclusive, at the time of screening.
  • Must be recreational drug user and agree not to consume any recreational drugs during the study.

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to lasmiditan, alprazolam, related compounds, or any components of the formulation, or a history of significant atopy.
  • Are currently seeking or participating in treatment for addiction or substance-related disorders, or have recovered from substance abuse disorder.
  • Are currently taking excluded prescription or over-the-counter (OTC) medications.
  • Have a history of significant sleep disorder, including sleep apnea or narcolepsy.
  • Have a history of orthostatic hypotension, vertigo, syncope, or presyncope.
  • Have a history of brain injury, including a history of concussions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo was administered orally in one of five treatment periods

    Drug: Placebo

  • Active comparator
    Alprazolam 2 milligram (mg)

    2 mg of alprazolam was administered orally in one of five treatment periods

    Drug: Alprazolam

  • Experimental
    Lasmiditan 100 mg

    100 mg of lasmiditan was administered orally in one of five treatment periods

    Drug: Lasmiditan

  • Experimental
    Lasmiditan 200 mg

    200 mg of lasmiditan was administered orally in one of five treatment periods

    Drug: Lasmiditan

  • Experimental
    Lasmiditan 400 mg

    400 mg of lasmiditan was administered orally in one of five treatment periods

    Drug: Lasmiditan

Interventions

  • Administered orally

    Also known as: LY573144

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores

    The Emax of Bipolar Drug Liking VAS Scores were derived as the maximum at-the-moment Drug Liking VAS score where the time to Emax was the corresponding time point at which the maximum score occurred. The bipolar Drug Liking VAS is consistent with FDA Guidance (January 2017) such that placebo should produce a score between 40 and 60 representing neutral drug-liking (ie, neither like nor dislike); a score ranging from 0 to 100 and a score of 0 indicates strong disliking, and a score of 100 indicates strong liking. Least squares mean (LS mean) was calculated using a linear mixed-effects model, including period, sequence, and treatment as fixed effects, and subject as a random effect, was used to evaluate the hypothesis tests of primary interest (at-the-moment Drug Liking) at the Emax.

    Time frame: Each Phase: 24 Hours

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan

    Pharmacokinetics (PK) defined as the maximum observed drug concentration (Cmax) of lasmiditan

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose

  2. PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])

    PK defined as the area under the curve of lasmiditan from zero to infinity (AUC\[0-∞\])

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose

  3. PD: Maximal Drug Effects (Emax) Visual Analog Scale (VAS)

    Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. Scales include: Overall drug liking (overall, my liking for this drug is) and ranges from 0 definitely not to 100 definitely so. Take Drug Again (I would take this drug again) and ranges from 0 definitely not to 100 definitely so. Good effects (I can feel good drug effects) and ranges from 0 definitely not to 100 definitely so. Bad effects (I can feel bad drug effects) and ranges from 0 definitely not to 100 definitely so. High (I am feeling) and ranges from 0 not at all high to 100 extremely high. Emax is derived as the maximum score across all postdose time points for each participant. Least Square (LS) Mean is calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.

    Time frame: Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose

  4. PD: Maximal Drug Effects (Emax) VAS (Hallucinations)

    Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The hallucinations scale is presented meaning (I am hallucinating) and ranges from 0 not at all to 100 extremely. Emax is derived as the maximum score across all postdose time points for each participant. Median and interquartile range are reported for each treatment group.

    Time frame: Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose

  5. PD: Minimum Drug Effects (Emin) Visual Analog Scale (VAS)

    Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The scales included: Alertness/Drowsiness (I am feeling) ranges from 0 very drowsy to 100 very alert. Agitation/Relaxation (my mood is) and ranges from 0 very relaxed to 100 very agitated. Emin is derived across all postdose time points for each participant. LS Mean was calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.

    Time frame: Each Phase:Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose

  6. PD: Mean Scores on Drug Similarity VAS Measures

    Participants marked a point on a 100-mm horizontal line that best represented their response to the given question. The endpoints of each electronic scale were marked with descriptive anchors on a scale from 0 to 100 (Fraser et al. 1961; Bond and Lader 1974; Bigelow 1991; Shram et al. 2010). In the "How similar" questions, ranges from 0 to 100 and a score of 0 indicates definitely not similar, and a score of 100 indicates definitely similar.

    Time frame: Each Phase: 24 Hours Post Dose

07

Results

Posted Jan 10, 2020

Participant flow

Qualification Phase Period 1
Participant flow — Qualification Phase Period 1
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started48480000000000
Received at least one dose of study drug47470000000000
Completed47470000000000
Not completed110000000000
Withdrew: Adverse event100000000000
Withdrew: Withdrawal by subject010000000000
Qualification Phase Period 2
Participant flow — Qualification Phase Period 2
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started47470000000000
Completed30280000000000
Not completed17190000000000
Withdrew: Adverse event010000000000
Withdrew: Failure to meet randomization criteria14150000000000
Withdrew: Lost to follow-up010000000000
Withdrew: Protocol violation200000000000
Withdrew: Withdrawal by subject120000000000
Treatment Phase Period 1
Participant flow — Treatment Phase Period 1
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started006656666656
Received at least one dose of study drug006656666656
Completed005555666655
Not completed001101000001
Withdrew: Withdrawal by subject001101000001
Treatment Phase Period 2
Participant flow — Treatment Phase Period 2
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started005555666655
Completed005555666655
Not completed000000000000
Treatment Phase Period 3
Participant flow — Treatment Phase Period 3
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started005555666655
Completed005555666655
Not completed000000000000
Treatment Phase Period 4
Participant flow — Treatment Phase Period 4
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started005555666655
Completed005555666654
Not completed000000000001
Withdrew: Withdrawal by subject000000000001
Treatment Phase Period 5
Participant flow — Treatment Phase Period 5
MilestoneQualification Phase - Alprazolam Then Placebo Sequence 1Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started005555666654
Completed005555666654
Not completed000000000000

Outcome measures

PrimaryPharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores

The Emax of Bipolar Drug Liking VAS Scores were derived as the maximum at-the-moment Drug Liking VAS score where the time to Emax was the corresponding time point at which the maximum score occurred. The bipolar Drug Liking VAS is consistent with FDA Guidance (January 2017) such that placebo should produce a score between 40 and 60 representing neutral drug-liking (ie, neither like nor dislike); a score ranging from 0 to 100 and a score of 0 indicates strong disliking, and a score of 100 indicates strong liking. Least squares mean (LS mean) was calculated using a linear mixed-effects model, including period, sequence, and treatment as fixed effects, and subject as a random effect, was used to evaluate the hypothesis tests of primary interest (at-the-moment Drug Liking) at the Emax.

Time frame:
Each Phase: 24 Hours
Reported as:
Least squares mean · millimeter (mm)
Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores
millimeter (mm)PlaceboAlprazolam - 2 mgLasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores53.0 ± 1.9485.4 ± 1.9468.6 ± 1.9473.3 ± 1.9476.6 ± 1.94
Statistical analysis
  • Placebo vs Alprazolam - 2 mg · Least squares (ls) mean difference: 32.4 · 90% CI 28.4 to 36.4
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 15.6 · 90% CI 11.7 to 19.6
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 20.3 · 90% CI 16.3 to 24.3
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 23.6 · 90% CI 19.6 to 27.6
  • Alprazolam - 2 mg vs Lasmiditan - 100 mg · Ls mean difference: 16.8 · 90% CI 12.8 to 20.8
  • Alprazolam - 2 mg vs Lasmiditan - 200 mg · Ls mean difference: 12.1 · 90% CI 8.10 to 16.1
  • Alprazolam - 2 mg vs Lasmiditan - 400 mg · Ls mean difference: 8.79 · 90% CI 4.8 to 12.8
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan

Pharmacokinetics (PK) defined as the maximum observed drug concentration (Cmax) of lasmiditan

Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan
nanogram/milliliter (ng/mL)Lasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan132 ± 37299 ± 35689 ± 34
SecondaryPK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])

PK defined as the area under the curve of lasmiditan from zero to infinity (AUC\[0-∞\])

Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*h/mL)
PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])
nanogram*hour/milliliter (ng*h/mL)Lasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg Dose
PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])856 ± 321810 ± 353920 ± 28
SecondaryPD: Maximal Drug Effects (Emax) Visual Analog Scale (VAS)

Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. Scales include: Overall drug liking (overall, my liking for this drug is) and ranges from 0 definitely not to 100 definitely so. Take Drug Again (I would take this drug again) and ranges from 0 definitely not to 100 definitely so. Good effects (I can feel good drug effects) and ranges from 0 definitely not to 100 definitely so. Bad effects (I can feel bad drug effects) and ranges from 0 definitely not to 100 definitely so. High (I am feeling) and ranges from 0 not at all high to 100 extremely high. Emax is derived as the maximum score across all postdose time points for each participant. Least Square (LS) Mean is calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.

Time frame:
Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
Reported as:
Least squares mean · mm
PD: Maximal Drug Effects (Emax) Visual Analog Scale (VAS)
mmPlaceboAlprazolam - 2 mgLasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
Overall Drug Liking53.1 ± 2.4186.2 ± 2.4171.7 ± 2.4172.2 ± 2.4177.4 ± 2.41
Take Drug Again52.0 ± 2.7086.0 ± 2.7071.1 ± 2.7072.7 ± 2.7077.3 ± 2.70
Good Effects10.8 ± 4.1080.5 ± 4.1046.4 ± 4.1062.9 ± 4.1063.8 ± 4.10
Bad Effects2.47 ± 3.2222.9 ± 3.227.51 ± 3.229.75 ± 3.2215.0 ± 3.22
Any Effects8.35 ± 4.0583.7 ± 4.0553.3 ± 4.0565.1 ± 4.0573.2 ± 4.04
High8.61 ± 3.8977.2 ± 3.8943.0 ± 3.8956.1 ± 3.8967.0 ± 3.89
Statistical analysis
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 33.1 · 90% CI 28.5 to 37.7
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 18.6 · 90% CI 14.0 to 23.2
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 19.1 · 90% CI 14.5 to 23.8
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 24.3 · 90% CI 19.7 to 28.9
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 34.0 · 90% CI 29.1 to 38.9
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 19.1 · 90% CI 14.2 to 24.0
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 20.6 · 90% CI 15.7 to 25.6
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 25.3 · 90% CI 20.3 to 30.2
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 69.7 · 90% CI 62.1 to 77.4
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 35.5 · 90% CI 27.9 to 43.2
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 52.0 · 90% CI 44.4 to 59.7
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 53.0 · 90% CI 45.4 to 60.6
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 20.4 · 90% CI 13.6 to 27.2
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 5.04 · 90% CI -1.76 to 11.8
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 7.28 · 90% CI 0.487 to 14.1
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 12.5 · 90% CI 5.69 to 19.3
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 75.4 · 90% CI 67.2 to 83.5
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 44.9 · 90% CI 36.8 to 53.0
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 56.8 · 90% CI 48.7 to 64.9
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 64.8 · 90% CI 56.7 to 73.0
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: 68.6 · 90% CI 60.6 to 76.6
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: 34.4 · 90% CI 26.4 to 42.4
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: 47.5 · 90% CI 39.5 to 55.5
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: 58.4 · 90% CI 50.4 to 66.3
SecondaryPD: Maximal Drug Effects (Emax) VAS (Hallucinations)

Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The hallucinations scale is presented meaning (I am hallucinating) and ranges from 0 not at all to 100 extremely. Emax is derived as the maximum score across all postdose time points for each participant. Median and interquartile range are reported for each treatment group.

Time frame:
Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
Reported as:
Median · mm
PD: Maximal Drug Effects (Emax) VAS (Hallucinations)
mmPlaceboAlprazolam - 2 mgLasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
PD: Maximal Drug Effects (Emax) VAS (Hallucinations)0 (0 to 0)0 (0 to 1.00)0 (0 to 0)0 (0 to 0)0 (0 to 0)
Statistical analysis
  • Placebo vs Alprazolam - 2 mg · Wilcoxon (Mann-Whitney) · p = <0.0001 · Mean difference (final values): 0
  • Placebo vs Lasmiditan - 100 mg · Wilcoxon (Mann-Whitney) · p = 0.0781 · Median difference (final values): 0
  • Placebo vs Lasmiditan - 200 mg · Wilcoxon (Mann-Whitney) · p = 0.0625 · Median difference (final values): 0
  • Placebo vs Lasmiditan - 400 mg · Wilcoxon (Mann-Whitney) · p = 0.0098 · Median difference (final values): 0
SecondaryPD: Minimum Drug Effects (Emin) Visual Analog Scale (VAS)

Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The scales included: Alertness/Drowsiness (I am feeling) ranges from 0 very drowsy to 100 very alert. Agitation/Relaxation (my mood is) and ranges from 0 very relaxed to 100 very agitated. Emin is derived across all postdose time points for each participant. LS Mean was calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.

Time frame:
Each Phase:Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
Reported as:
Least squares mean · mm
PD: Minimum Drug Effects (Emin) Visual Analog Scale (VAS)
mmPlaceboAlprazolam - 2 mgLasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
Alertness/drowsiness42.5 ± 1.9712.5 ± 1.9725.6 ± 1.9722.9 ± 1.9717.7 ± 1.97
Agitation/relaxation44.1 ± 1.9413.4 ± 1.9424.6 ± 1.9422.4 ± 1.9415.4 ± 1.94
Statistical analysis
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: -29.9 · 90% CI -34.0 to -25.9
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: -16.9 · 90% CI -20.9 to -12.8
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: -19.6 · 90% CI -23.6 to -15.5
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: -24.8 · 90% CI -28.8 to -20.8
  • Placebo vs Alprazolam - 2 mg · Ls mean difference: -30.8 · 90% CI -35.0 to -26.5
  • Placebo vs Lasmiditan - 100 mg · Ls mean difference: -19.5 · 90% CI -23.7 to -15.3
  • Placebo vs Lasmiditan - 200 mg · Ls mean difference: -21.7 · 90% CI -25.9 to -17.5
  • Placebo vs Lasmiditan - 400 mg · Ls mean difference: -28.8 · 90% CI -33.0 to -24.5
SecondaryPD: Mean Scores on Drug Similarity VAS Measures

Participants marked a point on a 100-mm horizontal line that best represented their response to the given question. The endpoints of each electronic scale were marked with descriptive anchors on a scale from 0 to 100 (Fraser et al. 1961; Bond and Lader 1974; Bigelow 1991; Shram et al. 2010). In the "How similar" questions, ranges from 0 to 100 and a score of 0 indicates definitely not similar, and a score of 100 indicates definitely similar.

Time frame:
Each Phase: 24 Hours Post Dose
Reported as:
Mean · score on a scale
PD: Mean Scores on Drug Similarity VAS Measures
score on a scalePlacebo - Qualification Phase1 mg Alprazolam - Qualification PhasePlacebo2 mg AlprazolamLasmiditan - 100 mgLasmiditan - 200 mgLasmiditan - 400 mg
How similar with cocaine /1.3 ± 3.55.8 ± 10.62.2 ± 6.66.1 ± 13.62.7 ± 4.214.6 ± 26.312.5 ± 23.3
How similar with caffeine2.9 ± 10.33.2 ± 6.01.5 ± 7.24.4 ± 9.72.2 ± 2.44.4 ± 9.84.1 ± 8.3
How similar to MDMA (Ectasy)4.7 ± 13.510.0 ± 20.41.4 ± 3.920.5 ± 23.710.6 ± 19.917.1 ± 28.218.7 ± 28.2
How similar to amphetamine or methamphetamine1.5 ± 5.44.3 ± 6.32.4 ± 6.03.9 ± 5.52.3 ± 2.54.6 ± 4.84.4 ± 6.2
How similar to phencyclidine (PCP)22.0 ± 30.60.5 ± 1.00.0 ± 0.026.7 ± 40.31.3 ± 1.524.0 ± 37.332.3 ± 43.7
How similar to codeine or morphine use11.4 ± 23.841.5 ± 35.18.1 ± 21.750.8 ± 31.230.9 ± 30.437.6 ± 31.745.9 ± 32.4
How similar to (lysergic acid diethylamide (LSD)1.2 ± 3.94.1 ± 6.94.2 ± 6.66.2 ± 7.53.5 ± 4.65.9 ± 5.57.2 ± 8.0
How similar to nicotine2.9 ± 11.85.1 ± 9.61.4 ± 5.53.8 ± 9.43.3 ± 11.03.6 ± 9.04.3 ± 8.6
How similar to cannabis10.8 ± 24.739.9 ± 33.58.9 ± 22.951.2 ± 30.329.9 ± 30.037.4 ± 29.641.7 ± 31.6
How similar to benzodiazepine14.4 ± 32.475.9 ± 36.213.1 ± 30.688.1 ± 22.657.2 ± 40.366.9 ± 38.774.6 ± 31.9
How similar to mushrooms0.0 ± 0.02.7 ± 3.82.1 ± 5.23.7 ± 6.12.1 ± 2.13.8 ± 5.74.9 ± 6.3
How similar to heroin0.0 ± 0.017.8 ± 38.1NA ± NANA ± NANA ± NANA ± NANA ± NA

Adverse events

Collected over From Baseline to Study Completion (Up to 2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Qualification Phase - Placebo0/95 (0%)0/95 (0%)8/95 (8.4%)
Qualification Phase - Alprazolam0/94 (0%)0/94 (0%)74/94 (78.7%)
Treatment Phase - Placebo0/55 (0%)0/55 (0%)12/55 (21.8%)
Treatment Phase - 2 mg Alprazolam0/53 (0%)0/53 (0%)49/53 (92.5%)
Treatment Phase - 100 mg Lasmiditan0/55 (0%)0/55 (0%)33/55 (60%)
Treatment Phase - 200 mg Lasmiditan0/55 (0%)0/55 (0%)42/55 (76.4%)
Treatment Phase - 400 mg Lasmiditan0/55 (0%)0/55 (0%)47/55 (85.5%)
Most frequent other events
Most frequent other events
EventQualification Phase - PlaceboQualification Phase - AlprazolamTreatment Phase - PlaceboTreatment Phase - 2 mg AlprazolamTreatment Phase - 100 mg LasmiditanTreatment Phase - 200 mg LasmiditanTreatment Phase - 400 mg Lasmiditan
SomnolenceNervous system disorders3/9552/942/5545/5318/5522/5530/55
Euphoric moodPsychiatric disorders1/9522/946/5523/5314/5527/5525/55
Feeling of relaxationGeneral disorders3/9520/941/5512/536/554/554/55
AmnesiaNervous system disorders0/950/940/5510/530/551/550/55
DizzinessNervous system disorders0/951/940/552/533/556/552/55
ParaesthesiaNervous system disorders1/950/940/551/534/556/555/55
AgitationPsychiatric disorders0/950/940/555/531/553/552/55
HeadacheNervous system disorders0/952/944/554/533/553/554/55
Upper respiratory tract infectionInfections and infestations1/950/941/550/533/550/551/55

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Overall Participants
Mean31.4 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall Participants
Female19
Male77
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Participants
Hispanic or Latino5
Not Hispanic or Latino91
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Participants
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American69
White24
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Participants
United States96
08

Study locations

1 site
  • Vince & Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2017, 2 months.

Results were first posted in Jan 2020, 2 years 1 month after primary completion.

Of 24 industry-sponsored phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 3 and three quarters within 9. This study's 2 months is below that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Sep 18, 2017
StartActual
Sep 15, 2017
Primary completionActual
Nov 20, 2017
CompletionActual
Nov 20, 2017
Results first posted
Jan 10, 2020
Last update
Jan 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03286218
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Sep 15, 2017
Primary completion
Nov 20, 2017
Completion
Nov 20, 2017
Results posted
Jan 10, 2020
Last update
Jan 10, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasmiditan

Start the discussion